70 results
Page 2 of 4
424B5
f6cyj42ee 6nd13k46o
9 Oct 18
Prospectus supplement for primary offering
6:51am
424B5
nkirdi92
29 Jun 18
Prospectus supplement for primary offering
7:23am
8-K
EX-10.1
rz9360ggvfwag5rke0p
24 Oct 14
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
12:00am
8-K
EX-10.47
wzr6fw00 rhfbo
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
EX-2.1
rpna6otq0cam5kvpax
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am